2015
Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors
Waks AG, Tolaney SM, Galar A, Arnaout A, Porter JB, Marty FM, Winer EP, Hammond SP, Baden LR. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Research And Treatment 2015, 154: 359-367. PMID: 26420402, DOI: 10.1007/s10549-015-3573-2.Peer-Reviewed Original ResearchConceptsPneumocystis jiroveci pneumoniaCases of PCPEarly-stage breast cancerBreast cancerJiroveci pneumoniaAC chemotherapyRisk factorsDana-Farber Cancer Institute/BrighamNon-metastatic breast cancer patientsAdjuvant anthracycline-based chemotherapyEarly-stage breast cancer treatmentAdriamycin/cyclophosphamideDose-dense ACAnthracycline-based chemotherapyDose-dense scheduleBreast cancer patientsBreast cancer treatmentEquivalents/dayCalculate incidenceCorticosteroid doseNausea prophylaxisSame chemotherapyOpportunistic infectionsOverall incidencePCP incidence
2008
Lymphopenia Associated with Adjuvant Anthracycline/Taxane Regimens
Tolaney SM, Najita J, Winer EP, Burstein HJ. Lymphopenia Associated with Adjuvant Anthracycline/Taxane Regimens. Clinical Breast Cancer 2008, 8: 352-356. PMID: 18757263, DOI: 10.3816/cbc.2008.n.041.Peer-Reviewed Original ResearchConceptsDose-dense ACPneumocystis carinii pneumoniaDose-dense chemotherapyCells/mm3Absolute lymphocyte countAbsolute neutrophil countAlbumin-bound paclitaxelLymphocyte countCohort 2Cohort 1Lymphocyte depletionOpportunistic infectionsCohort 3Day 1Cases of PCPLow absolute lymphocyte countDana-Farber Cancer InstitutePhase II clinical trialDoxorubicin/cyclophosphamideGrade 3/4 lymphopeniaGrade 4 lymphopeniaHIV-negative patientsMedian lymphocyte countPhase II studyCohort of patients